Kadcyla In pAtients With bRAin Metastasis

NCT03203616 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped As most HER2+ patient develop brain mets while on/after having received TDM1, it has proven to be an insurmountable challenge to recruit patients

Conditions

Metastatic HER2-positive Breast Cancer With Brain Metastasis

Interventions

DRUG: KADCYLA 160 MG Injection

Sponsor

Jules Bordet Institute